AecorBio

AecorBio is an IND-stage biopharmaceutical company based in Menlo Park, California, focused on developing bioactive peptide therapeutics to address treatment resistance in oncology, immunology, and neurology. Spun out from Hofseth BioCare, the company leverages a proprietary high-throughput platform to identify peptides that restore cellular homeostasis, particularly by normalizing iron metabolism. Its lead candidate, FT-002a, is a first-in-class oral peptide co-therapy designed to reverse resistance to androgen receptor inhibitors in advanced prostate cancer. AecorBio's broader pipeline includes programs for platinum-resistant ovarian cancer, steroid-resistant asthma, and restless leg syndrome, all targeting root causes of therapeutic failure. The company integrates AI-driven design with marine-derived peptide discovery to create a multi-asset portfolio supported by strong intellectual property and academic collaborations.